At Fosun Health, pancreatic cancer diagnosis must answer three critical questions: Is it cancer? Can it be surgically removed? What are its genetic drivers? Our integrated pathway delivers all answers within days:
The cornerstone of pancreatic cancer imaging. High-quality thin-slice CT reveals the tumor's exact location, size, and its relationship with major arteries (celiac axis, superior mesenteric artery) and veins (portal vein, superior mesenteric vein)—directly determining whether the tumor is resectable, borderline resectable, or locally advanced. This is the most important scan for surgical planning.
The most accurate tool for both T-staging and tissue diagnosis. EUS visualizes the tumor's depth and its invasion into adjacent vessels with millimeter precision. EUS-guided fine-needle aspiration (EUS-FNA) obtains tissue samples with over 90% diagnostic accuracy—the pathological gold standard. For small cystic lesions, EUS with contrast enhancement or elastography further improves accuracy.
MRI offers superior soft-tissue resolution for characterizing cystic pancreatic tumors and assessing small liver metastases. MRCP (Magnetic Resonance Cholangiopancreatography) non-invasively visualizes the bile and pancreatic ducts, detecting obstructions caused by the tumor.
Detects occult distant metastases (especially in the liver, peritoneum, or lungs) that CT or MRI may miss. For patients with high-risk features or suspected metastatic disease, PET-CT provides whole-body staging before any treatment decision.
Using NGS (Next-Generation Sequencing), we analyze KRAS (including G12C, G12D, G12V, G12R), BRCA1/2, PALB2, HER2 amplification, MSI/dMMR, NTRK fusions, and over 300 cancer-related genes. This determines your eligibility for KRAS G12C inhibitors (adagrasib, sotorasib), PARP inhibitors (olaparib for BRCA-mutated disease), HER2-targeted therapies (trastuzumab deruxtecan/T-DXd), immunotherapy (pembrolizumab for MSI-H/dMMR tumors), NTRK inhibitors, or clinical trials of next-generation KRAS G12D and pan-RAS inhibitors—ensuring your treatment is matched to your tumor's unique biology.
